Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results